Key facts
- Genomics’s last known valuation is $161.6M.
- It has raised $142.2M; the latest was Later Stage VC ($44.0M) in Nov 2024.
- Notable investors include F-Prime Capital, Eight Roads, Salica Investments, University of Oxford, Oxford Science Enterprises — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genomics
Developer of a genetic inference technology designed to lead the genomic transformation by finding new drug targets for serious diseases. The company uses an analytical platform for genomic sequence data investigation and consultancy, which maximizes the impact of DNA sequencing and helps to identify individuals at risk of particular diseases, enabling pharmaceutical businesses to avail a genomic engine that de-risks the drug development process and provides improved healthcare.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2014
- Employees
- 195
- Website
- genomics.com/
- Ownership
- Privately Held (backing)
Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genomics in its N-PORT filings yet. We sweep new filings monthly.